Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
Authors
Keywords
-
Journal
Lancet HIV
Volume 8, Issue 11, Pages e668-e678
Publisher
Elsevier BV
Online
2021-10-16
DOI
10.1016/s2352-3018(21)00184-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries
- (2021) Babatunde Akinwunmi et al. SEXUALLY TRANSMITTED INFECTIONS
- Predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine
- (2021) Amy G. Cutrell et al. AIDS
- Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
- (2021) Chloe Orkin et al. Lancet HIV
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
- (2020) Chloe Orkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
- (2020) Susan Swindells et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy
- (2020) Giuliano Rizzardini et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- (2020) Michael S. Saag et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2020) Edgar T Overton et al. LANCET
- Understanding Global HIV Stigma and Discrimination: Are Contextual Factors Sufficiently Studied? (GAPRESEARCH)
- (2019) Bach Xuan Tran et al. International Journal of Environmental Research and Public Health
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
- (2019) Willem D.F. Venter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
- (2019) Joseph J. Eron et al. ANTIVIRAL RESEARCH
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- 1329. Experiences and Emotional Challenges of Antiretroviral Treatment (ART)—Findings from the Positive Perspectives Study
- (2019) Patricia De Los Rios et al. Open Forum Infectious Diseases
- Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
- (2018) Josep M Llibre et al. LANCET
- Interest of Youth Living with HIV in Long-Acting Antiretrovirals
- (2018) Ethel D. Weld et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
- (2018) Pedro Cahn et al. LANCET
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
- (2017) David A Margolis et al. LANCET
- Beyond viral suppression of HIV – the new quality of life frontier
- (2016) Jeffrey V. Lazarus et al. BMC Medicine
- Adherence to Antiretroviral Therapy and Virologic Failure
- (2016) Woldesellassie M. Bezabhe et al. MEDICINE
- Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis
- (2016) Zara Shubber et al. PLOS MEDICINE
- Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials
- (2014) Jean B. Nachega et al. CLINICAL INFECTIOUS DISEASES
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Adherence to Antiretroviral Therapy and Its Effect on Survival of HIV-Infected Individuals in Jharkhand, India
- (2013) Sandeep Rai et al. PLoS One
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now